semaglutide absorption A Review of the Oral in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity UV-Vis Spectrum of Semaglutide |

Lancet (2019) 394:12130

When you eat high-fiber foods including grains, avocados, legumes, raspberries, and nuts your body releases more GLP-1 hormones

Southern Weight Loss provides GP shared care and surgical escalation pathways

If you take insulin or sulfonylureas with GLP-1 therapy, check your blood glucose when experiencing cognitive symptoms, as hypoglycemia can mimic brain fog

It acts centrally and peripherally to: Reduce appetite and caloric intake, leading to average weight loss of about 1525% of baseline body weight with longterm use in obesity. Improve glycemic control, insulin sensitivity, and cardio metabolic risk factors such as blood pressure and lipids. Across large phase 3 obesity and diabetes trials, common adverse events are gastrointestinal (nausea, vomiting, diarrhea, constipation, abdominal pain), while serious but less common risks include pancreatitis, gallbladder disease, rare kidney injury, and thyroid tumors in rodent models